Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy, privileged insights into optimal therapeutic selection based on the latest clinical trial data, and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.
Upon completion of this activity, participants should be better able to:
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology
Chief, Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital
Associate Cancer Center Director, Translational Research
Yale Cancer Center
New Haven, CT
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT
Head, Fingerland Department of Pathology
Charles University, Medical Faculty
Hradec Králové, Czech Republic
Featured RMEI CE Activities – Earn CE Credit(s)
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
